08:43 AM EDT, 08/20/2024 (MT Newswires) -- Organon (OGN) said Tuesday it has expanded its agreement with Eli Lilly ( LLY ) to solely distribute and market the migraine drug Emgality in 11 additional markets.

The new markets include Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey, and the UAE, the healthcare company added.

Under the terms of the agreement, Eli Lilly ( LLY ) will receive a $22.5 million upfront payment and sales-based milestone payments, Organon said.

Eli Lilly ( LLY ) will continue to manufacture the product, according to Organon.

The two firms signed a deal in December for Organon to solely distribute and market Emgality in Europe.

Organon's stock was 0.2% higher in recent Tuesday premarket activity, while Eli Lilly ( LLY ) shares rose 1.6%.

Price: 21.00, Change: +0.04, Percent Change: +0.19